SI-101

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameSI-101
Drug Alias NameSIRPant-MRB-1355SI-101
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsLymphoma, T-Cell, Cutaneous +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSIRPant Immunotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSIRPant Immunotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsLymphoma, T-Cell, Cutaneous +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A